Open Call H2020-SMEINST-1-2015: Horizon 2020 Dedicated SME Instrument Phase 1 and 2

European CommissionThe dedicated SME instrument's supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target.

The SME Instrument offers small and medium-sized businesses the following:

  • Business innovation grants for feasibility assessment purposes (optional phase I): EUR 50,000 (lump sum) per project (70% of total cost of the project);
  • Business innovation grants for innovation development & demonstration purposes (possible phase II): an amount in the indicative range of EUR 500,000 and 2,5 million (70% of total cost of the project as a general rule);
  • Free-of-charge business coaching (optional in phases I and II), in order to support and enhance the firm's innovation capacity and help align the project to strategic business needs;
  • Access to a wide range of innovation support services and facilitated access to risk finance (mostly in optional phase III), to facilitate the commercial exploitation of the innovation.

Topics, further information, documents and submission service:

Deadline Date: 25-11-2015 17:00:00 (Brussels local time)
Cut-off date(s):

  • 18-03-2015 17:00:00 (Brussels local time)
  • 17-06-2015 17:00:00 (Brussels local time)
  • 17-09-2015 17:00:00 (Brussels local time)
  • 25-11-2015 17:00:00 (Brussels local time)

Most Popular Now

Almirall Takes a Leap into Dermatology D…

Almirall, S.A. (ALM) has launched its first call for innovation to start-ups focused on dermatology digital health. This initiative is the first step in the creation of an accelerator programme...

The Bristol-Myers Squibb-Pfizer Alliance…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib)...

Philips and Spencer Health Solutions Exp…

Building on their successful partnership providing medication adherence solutions to high-acuity patients in the U.S. Royal Philips (NYSE:PHG, AEX:PHIA), a global leader in health technology, and Spencer Health Solutions announced...

Using Artificial Intelligence to Predict…

Thyroid nodules are small lumps that form within the thyroid gland and are quite common in the general population, with a prevalence as high as 67%. The great majority of...

Bayer Launches LifeHub UK Focused on Art…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The new hub is the seventh pillar of Bayer's global network...

AI could Offer Warnings about Serious Si…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ damage and even death. Now, researchers at...

NHS Health Tech Team of the Year Named

A pioneering NHS trust has been recognised at the 2019 HTN Awards for its innovative work using InterSystems technology to help enhance care for hundreds of thousands of patients. North...

Philips and Klinikum Stuttgart Hospital …

Royal Philips (NYSE:PHG, AEX:PHIA), a global leader in health technology, and German Klinikum Stuttgart hospital, the largest provider in the region, announced they have signed a comprehensive 10-year innovation partnership...

Heartbeat Labs Hired Babylon Health's Ch…

The Berlin-based digital health platform Heartbeat Labs hired Chad Jennings as Chief Product Officer (CPO). Chad is a product and design leader with twenty years of experience at the intersection...

Combination of AI & Radiologists mor…

An artificial intelligence (AI) tool - trained on roughly a million screening mammography images - identified breast cancer with approximately 90 percent accuracy when combined with analysis by radiologists, a...

Abbott and Omada Health Partner to Offer…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care...

First Entirely Digital Clinical Trial En…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study. The...